Skip to main content

Novo Nordisk's weight loss drug Wegovy slashes risk of serious heart events

The findings could expand use of Wegovy and help Novo maintain its lead over Eli Lilly, whose competing weight-loss drug Zepbound was just approved in the U.S.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.